| Breast Neoplasms |
NCT01130259: An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer |
|
|
| No Longer Available | N/A | | US | iniparib, BSI-201 | Sanofi | Breast Cancer | | | | |
NCT02755987: Expanded Access to ANG1005 for Individual Patients |
|
|
| No Longer Available | N/A | | US | ANG1005 | Angiochem Inc | Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis | | | | |
NCT01120561: A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer |
|
|
| No Longer Available | N/A | | US | trastuzumab-MCC-DM1 | Genentech, Inc. | Metastatic Breast Cancer | | | | |
|
NCT03067935: Individual Patient Expanded Access-Glembatumumab Vedotin |
|
|
| No Longer Available | N/A | | NA | glembatumumab vedotin | Celldex Therapeutics | Metastatic gpNMB Expressing Triple Negative Breast Cancer | | | | |
NCT02142868: Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate |
|
|
| No Longer Available | N/A | | Canada, US | Palbociclib, Ibrance, Letrozole, Femara | Pfizer | Advanced Breast Cancer (Female) | | | | |
| Recruiting | N/A | 420 | US | Permanent Breast Seed Implant (PBSI), Breast Microseed Treatment | Concure Oncology-Breast Microseed Inc. | Breast Neoplasms | 07/21 | 07/26 | | |
| Recruiting | N/A | 200 | US | Visica 2 Treatment System, Visica Breast Therapy | Sanarus Technologies, Inc. | Breast Cancer | 12/21 | 06/23 | | |
